ABSTRACT
INTRODUCTION
X-linked severe combined immunodeficiency (X-SCID) is caused by mutations in the gene encoding the common γ chain (γc), a shared signal transducing subunit of the interleukin (IL)-2, IL-4, IL-7, IL-9, IL-15, and IL-21 receptors [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Defects in the γc account for approximately 50% of cases of SCID and most cases of T -B + SCID [11] . In humans, the disease is characterized by low to absent peripheral T-cells and natural killer (NK) cells and normal or elevated levels of peripheral B-cells and by a marked inability to mount effective cell-mediated and humoral immune responses. If not successfully treated by bone marrow transplantation (BMT), X-SCID is fatal within the first 2 years of life [12] . This severe phenotype of X-SCID can be attributed to the pleiotropic effects of γc-containing receptors on the development and maintenance of immune
Transplantation of X-Linked Severe Combined Immunodeficient Dogs with CD34
+ Bone Marrow Cells
B B & M T
competence. Thymopoiesis requires IL-7; IL-15 and IL-21 are needed for generation and function of NK cells; IL-2 is necessary for clonal expansion of mature T-lymphocytes after activation; and IL-4 is required for B-lymphocyte immunoglobulin class switching [10, 13] . Since the first BMT for X-SCID in 1968, advances in BMT and T-cell-depletion techniques have allowed virtually every X-SCID patient to be treated by either HLA-identical or haploidentical BMT [14] [15] [16] . Despite the success of haploidentical BMT for X-SCID, serious clinical complications still exist, including failure of engraftment, Epstein-Barr virus-associated lymphoproliferative disease, graft-versushost disease, and a failure to reconstitute normal humoral immunity even after successful functional T-cell engraftment [15] [16] [17] . The failure to reconstitute normal humoral immune function has been observed after both haploidentical and HLA-matched BMT and has been correlated most strongly with a failure to engraft donor-derived B-cells [16] [17] [18] . Because of these problems, there is continuing impetus to develop better and more effective protocols for treatment of X-SCID using both conventional BMT and gene-transferbased protocols.
Successful treatment of X-SCID has also been achieved using retrovirally mediated gene transfer to introduce a normal copy of the γc gene into bone marrow progenitor cells [19] . Because of the selective advantage that corrected X-SCID T-lymphoid progenitors would have compared to uncorrected cells, the ability to correct even 1 bone marrow progenitor cell may have clinical benefit in patients with X-SCID. Indeed, an X-SCID patient has been described in whom a spontaneous reversion of a γc mutation in a single T-cell precursor led to the production of a diverse T-cell repertoire and partial amelioration of the X-SCID phenotype [20, 21] .
Mice rendered γc deficient by homologous recombination and dogs with spontaneous canine X-SCID are 2 animal models available for testing of either allogeneic BMT or gene transfer for the treatment of X-SCID. The γc knockout mice, unlike humans, have severe B-and T-lymphopenia that is most likely due to the increased importance of IL-7 in mouse B-cell lymphopoiesis [22] [23] [24] . Unlike the mouse model, the canine model of X-SCID is homologous to the human disease, with affected animals lacking mature T-cells because of abnormal thymopoiesis but having phenotypic B-cells with intrinsic defects in class switching [25] [26] [27] [28] . Dogs with X-SCID typically succumb to overwhelming infection within the first 4 months of age if not successfully treated. We have previously shown that the immune systems of X-SCID dogs that have undergone transplantation with normal unfractionated bone marrow cells reconstitute normal B-and T-cell function [29, 30] . Both mice and dogs have been used to test γc gene transfer using human γc vectors [31] [32] [33] .
CD34 is a 110-kD heavily glycosylated cell surface protein that is expressed on a subpopulation of bone marrow cells that are capable of multilineage engraftment in primates and humans [34] [35] [36] . Recently the canine CD34 gene was cloned, and a monoclonal antibody to the antigen was produced [37, 38] . Subsequently, transplantation of canine CD34 + cells into irradiated hosts has led to radioprotective reconstitution of the bone marrow compartment, suggesting that CD34 is also a marker for dog bone marrow progenitor cells [39] . To further evaluate the role of CD34 + cells in lymphohematopoietic development, we have used the CD34 + population of normal canine bone marrow for transplants in X-SCID dogs. The results indicate that CD34 + canine marrow cells contain T-and B-lymphoid progenitors capable of immune reconstitution after transplantation into X-SCID dogs, with outcomes similar to those observed after human clinical transplantation. These experiments establish the X-SCID dog as a valuable model for evaluating and enhancing both BMT and gene therapy protocols for X-SCID.
MATERIALS AND METHODS

X-SCID Genotyping and Dog Leukocyte Antigen Typing
X-SCID dogs were derived from a breeding colony established from a carrier female that harbored a 4-base pair (bp) deletion in the first exon of the γc gene [27] . Diagnosis of X-SCID pups employed a polymerase chain reaction (PCR)-based mutation detection assay that was performed at less than 1 week of age [27] . Inheritance of dog leukocyte antigen (DLA) alleles within families was determined by a PCR technique based on the inheritance of a microsatellite locus within the class II region of the DLA and was used to select matched healthy sibling donors [40] . Primer sequences LUC2202 reverse 5′-TCTGTGGGAAGAG GTAAGTTCA-3′ and LUC2202 forward 5′-CGTTCT GCTCACATTTCGTTAT-3′ were used with 30 cycles of PCR programs 94°C-1′, 62°C-1′, and 72°C-1′. Amplicons were visualized on an 8% nondenaturing polyacrylamide gel. The presence of matching bands was used to identify a DLA-matched sibling donor for each affected X-SCID dog.
Transplantation in X-SCID Dogs
All experiments were performed in accordance with the protocols approved by the University of Pennsylvania Institutional Animal Care and Use Committee (IACUC# 360600). Healthy DLA-matched donors were killed and their bones obtained. The bones were cracked, scraped, and flushed with RPMI 1640 medium. The marrow was teased apart and passed through a sterile 70-µm cell strainer (Becton Dickinson, Franklin Lakes, NJ). The resulting cell suspension was centrifuged on a Ficoll-Hypaque 1.077 gradient (Sigma, St Louis, MO) to remove red blood cells and then washed twice with phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA) and 100 U/mL DNaseI. Cells were resuspended at a final concentration of 1 × 10 8 cells/mL in a PBS solution containing 2 mmol/L EDTA, 0.1% BSA, and biotinylated anticanine CD34 antibody 1H6 at 40 µg/mL [39] . Cells were resuspended and then labeled with the secondary antimouse immunoglobulin G (IgG) MACS magnetic microbeads according to the manufacturer's protocol (Miltenyi, Auburn, CA). Labeled cells were selected on varioMACS columns as recommended by the manufacturer. Aliquots of positively selected cells were labeled with phycoerythrin (PE)-labeled streptavidin (Jackson Immunoresearch, West Grove, PA) and analyzed on a FACScan flow cytometer (Becton Dickinson, San Jose, CA) to determine the purity of the eluted cells. X-SCID recipients were intravenously catheterized and infused with irradiated (5400 cGy) CD34 -cells 15 minutes prior to infusion of the CD34 + selected cell population [41] . None of the dogs received pretransplantation conditioning.
Monitoring of X-SCID Dogs after Transplantation
The X-SCID dogs that underwent transplantation were monitored for evidence of engraftment at 4-week intervals. Assays that were performed included proliferation assays, complete blood cell count, flow cytometric analysis of lymphocyte subsets, and determination of serum IgG levels. For proliferation assays and flow cytometry, EDTA anticoagulated blood was obtained and diluted 1:1 in Hanks' balanced salt solution (HBSS) without Ca ++ or Mg ++ , layered over a 1.066 Ficoll-Hypaque gradient, and centrifuged at 400g for 20 minutes [42] . Peripheral blood mononuclear cells (PBMCs) were subsequently washed twice in HBSS, counted, and resuspended in RPMI 1640 supplemented with 10% fetal calf serum.
Proliferation Assays
PBMCs were plated in triplicate at 10 5 cells per well in a 96-well microtiter plate (Costar, Corning, NY) and incubated for 2 days at 37°C in a humidified 5% CO 2 incubator in triplicate with concentrations of phytohemagglutinin (PHA-P) (Sigma) varying from 1 to 4 µg/mL. Tritiated thymidine, 0.5 µCi (ICN, Costa Mesa, CA), was added to cultures after 2 days, and cells were harvested on glass microfiber filters (Whatman, Maidstone, England) using an automated cell harvester after 18 hours of additional incubation. Filter disks were removed, suspended in liquid scintillation cocktail (Ecolume, ICN), and counted in a LS 6500 scintillation counter (Beckman Coulter, Fullerton, CA)
Flow Cytometry
Staining was performed on aliquots of 1 × 10 6 Ficoll separated peripheral blood lymphocytes. PBMCs were washed in PBS containing 1% BSA, centrifuged, resuspended in PBS-BSA, and incubated for 20 minutes at 4°C with fluorescein isothiocyanate (FITC)-labeled antibodies to canine surface Ig (Rockland, Gilbertsville, PA) or unlabeled monoclonal antibodies to canine CD3 (CA17.2A12), CD4 (LSM-12.125), CD8 (LSM-4.78), CD21 (CA2.1D6), CD45RA (CA4.1D3), and CD3-like (LSM-8.358). For indirect labeling, PBMCs were washed twice with PBS-BSA and incubated with labeled secondary antibodies, FITC antimouse-specific IgM, or PE-labeled antimouse IgG-specific antibodies (Jackson Immunoresearch). Analysis of 10,000 events was performed using a FACSCalibur flow cytometer (Becton Dickinson). For cell sorting, PBMCs were stained with FITC-labeled anticanine CD3 and PE-labeled anticanine CD21. Cells were sorted by fluorescence into B-cell and T-cell fractions using FACSVantage and FACStar flow cytometers (Becton Dickinson).
Quantification of Serum IgG
Serum IgG was determined by radial immunodiffusion using canine IgG-specific plates (Bethyl, Montgomery, TX).
Assessment of Antigen-Specific Antibody Response
After donor cells were detected in dogs that underwent transplantation, the dogs were immunized intramuscularly with 0.5 mL tetanus toxoid (Lederle, Pearl River, NY). Animals were reimmunized with tetanus toxoid 2 weeks after the initial immunization. Serum samples were obtained from the immunized animals at weekly intervals for 4 weeks after the initial immunization. IgG-specific tetanus toxoid-specific antibody was determined using an enzymelinked immunosorbent assay (ELISA). Ninety-six-well ELISA plates (Costar) were coated overnight at 4°C with 200 µL of carbonate buffer (pH 9.6) containing 0.5 Lf units/mL of tetanus toxoid (Wyeth-Ayerst Laboratories, Marietta, PA). The plates were washed 3 times with PBS-0.05% Tween 20 (PBS-T). Serial 2-fold serum dilutions starting at 1:250 were made in buffer, and 200 mL was added to the antigen-coated wells. All samples were tested in duplicate. The plates were incubated at room temperature for 2 hours and washed 3 times with PBS-T. Subsequently, the plates were incubated for 2 hours at room temperature with peroxidase-labeled antidog IgG (γ heavy chain specific, Bethyl) diluted to 1:5000 in PBS-T. Plates were washed 3 times with PBS-T and then incubated for 20 minutes with 200 µL of o-phenylenediamine + 0.014% H 2 O 2 substrate solution (Sigma). The reaction was stopped by the addition of 50 µL of 1N H 2 SO 4 to each well. Absorbance at 490 nm was measured by a microplate ELISA reader (Molecular Devices, Menlo Park, CA). Endpoint titers were determined by calculating the reaction of each test sample to the negative preimmunization sample. A ratio of >2.0 with an optical density reading >0.2 was considered positive.
Chimerism Detection Assay
DNA was extracted from sorted cell populations (Gentra Systems, Minneapolis, MN), and PCR was performed using primers that flank the 4 bp of the γc gene that are missing in affected X-SCID dogs. The 5′ primer was labeled with 32 P. Products from the PCR reaction were separated on a standard 6% denaturing polyacrylamide sequencing gel by electrophoresis at 2000 V for 7 hours. Gel data were captured using a GS525 storage phosphorimaging system (BioRad, Hercules, CA) and analyzed using Multianalyst software. Background counts were subtracted, and then the data were normalized to the actual ratio of 32 P in the larger (169-bp normal) and smaller (165-bp mutant) PCR products seen from the control carrier female. This procedure corrects for any differences in PCR efficiency between the 165-and 169-bp products. After the data were adjusted based on the control carrier female (which was consistently between 47% and 53%), the percentage of donor cells was calculated as the percentage of counts in the normal band compared to the total counts in both bands. All data were within the capacity of the phosphoimager to detect 32 P in a linear range. Consequently, the percentage of donor cells reported is more accurate than the percentage calculated by visual examination of the computer-generated gel image.
RESULTS
Bone Marrow Transplantation
Six dogs that were between 1 and 3 weeks of age received CD34 + cell doses that ranged from 1.2 to 40.0 × 10 6 cells/kg (Table) . The purity of the CD34 + cells was greater than 96% except in 1 recipient (R862).
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Normalization of Lymphocyte Subsets
During the first 4 weeks of life, X-SCID dogs may have absolute lymphocyte counts and B-cell numbers that are normal, whereas T-cells have invariably been absent at the time of BMT [25, 26, 29] . At 1 month post-BMT, R860, the animal that received the highest dose of CD34 + cells, had normal absolute lymphocyte numbers (Figure 1 ). The remaining animals had abnormally low absolute lymphocyte numbers at 1 month post-BMT. By 2 months post-BMT, lymphocyte counts had normalized in all of the animals except R775, the animal that received the lowest dose of CD34 + cells. This dog continued to have marginal to subnormal lymphocyte counts throughout the study period of 6 months. Percentages of T-cells ( Figure 2A ) and absolute numbers of T-cells ( Figure 2B ) were normalized in all the animals except R775 at 2 months post-BMT. In R775, the percentage of T-cells was not normalized until 3 months after transplantation, and the absolute number of T-cells did not reach normal levels within the study period. Percentages of B-cells ( Figure 2C ) remained above normal in 4 of the animals at 1 month after transplantation but had normalized in all the animals but R862 by 2 months post-BMT. Absolute numbers of B-cells were at or above normal in all the animals throughout the study period ( Figure 2D ).
Reconstitution of T-Cell Function
Proliferation to PHA was used to assess the development of mitogen-responsive T-cells (Figure 3) . At 1 month post-BMT, only 1 animal, R860, had normal lymphocyte proliferation. By 2 months post-BMT, all of the animals except R775, the dog that received the lowest dose of CD34 + cells, had normal responses to PHA. This dog did not attain normal levels of proliferation to PHA until 3 to 4 months after transplantation. After normalization, proliferative responses were stable throughout the remainder of the study.
The percentage of T-cells that were positive for the RA isoform of CD45 was assessed to distinguish newly generated naïve T-lymphocytes from peripherally expanded T-cells [43] . This assessment was important because over time X-SCID dogs that do not receive transplants can develop nonfunctional T-cells that express an activated CD45RO phenotype [44] . By 2 months post-BMT, all animals except R775 showed normal percentages of CD45RA + T-cells (Figure 4) . Additionally, sorted PBMC fractions from the dogs that underwent transplantation showed that virtually all of the T-cells present in these animals after 2 months of age were donor derived. The development of donor-derived T-cells was similar to that observed with unfractionated bone marrow [29, 30] .
Reconstitution of B-Cell Function
The reconstitution of B-cell function in animals that underwent transplantation was assessed by measuring serum IgG levels, evaluating the IgG antibody response to tetanus toxoid, and evaluating the percentage of engrafted donor B-cells. IgG levels in these dogs showed a generally increasing trend after transplantation in all of the animals except R775 and R889 ( Figure 5 ). The 4 dogs with increasing IgG levels had reached normal levels by 6 months post-BMT. High initial readings for IgG can be explained by the presence of maternally derived IgG.
In our previous transplantation studies using unfractionated bone marrow, virtually all of the T-cells post-BMT were of donor origin, whereas 30% to 50% of the total peripheral B-cells were of donor origin. The engraftment of donor B-cells in the recipients of CD34 + cells was assessed using a similar PCR-based assay ( Figure 6 ). Two of the recipients had at least 15% donor B-cells. Two of the recipients had low levels (2%-4%) of donor B-cells, and 2 animals had <2% donor B-cells.
Animals were also tested for their ability to produce a specific IgG antibody response to a neoantigen, tetanus toxoid ( Figure 7) . The 2 animals that showed the highest level of donor B-cell engraftment, R860 and R743, also had nearnormal levels of antitetanus IgG. R862, R775, and R889 had undetectable or low levels of detected donor B-cells and also had correspondingly low tetanus toxoid IgG antibody responses. One animal (R868) had low levels of donor B-cell engraftment and a good tetanus toxoid response.
Details of Infused Bone Marrow Cells
DISCUSSION
Previous studies have documented the ability of autologous and allogeneic DLA-identical canine CD34 + cells to rescue lethally irradiated normal dogs with kinetics of neutrophil and platelet recovery similar to those observed using unfractionated bone marrow [38, 39] . This study extends those observations by demonstrating that highly purified DLA-identical canine CD34 + bone marrow cells are capable of engrafting donor B-and T-cells in nonablated X-SCID dogs. Although studies have shown that a population of human CD34
-cells also contains hematopoietic stem cell activity, it is unlikely that CD34 -cells contributed to the immunologic reconstitution seen in the dogs that underwent transplantation [45, 46] . In one study, transplantation of 10 7 autologous canine CD34 -cells/kg failed to rescue lethally irradiated normal adult dogs, with all 3 dogs dying by 20 days posttransplantation [38] .
The canine X-SCID transplantations described in this study are most similar to those performed in human X-SCID patients who undergo transplantation within the first few months after birth. Two recent studies evaluating a large cohort of SCID patients who underwent BMT showed that young patient age at transplantation influences survival outcome [16, 47] . 
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The kinetics of T-cell engraftment observed with our CD34 + transplants were comparable to both those seen in human X-SCID patients receiving transplants of T-celldepleted HLA-identical or haploidentical bone marrow cells and those seen in our previous studies of canine X-SCID using unfractionated bone marrow containing less than 1.5% mature T-cells. The proportions and absolute numbers of T-cells reached normal levels between 2 and 3 months posttransplantation in all but 1 dog, R775, which received the lowest dose of CD34 + bone marrow cells. R775 remained T-lymphopenic throughout the study. It is unlikely that any contaminating mature T-cells in the CD34 + cell preparations contributed to the T-cell engraftment in the dogs that underwent transplantation, because the majority of the T-cells were naïve CD45RA + lymphocytes consistent with their being recent thymic emigrants [43, 48] . It is likely that the majority of the CD3 + CD45RA + cells observed post-BMT were CD4 + T-cells and were not from extrathymic expansion of CD8 + T-cells [49] , because only 9.1% ± 3.1% of the T-cells in the animals were CD8 + at 2 months post-BMT (data not shown). The in vitro proliferative response to T-cell mitogenic stimulation followed similar kinetics, with normal responses observed between 2 and 3 months posttransplantation with the exception of R775, in which the development of a normal proliferative response was delayed.
The consistent development of donor-derived T-cells in the nonmyeloablated X-SCID dogs is in contrast to the results seen with B-cell engraftment. In the present study, 2 of 6 dogs developed significant numbers of donor-derived B-cells (>15% of total B-cells), whereas 2 of the dogs had <2% donor B-cells. Both dogs with high levels of B-cell engraftment produced normal levels of antigen-specific IgG antibodies after immunization with tetanus toxoid. In contrast, the animals with low levels of B-cell engraftment generally had deficient humoral function. These results differ from those of our previous studies using unfractionated bone marrow, in which all X-SCID dogs that developed T-cell reconstitution also developed 20% to 50% donor-derived B-cells and normal levels of antigen-specific IgG antibody [29, 30] .
Although this study was not designed to test the effect of CD34 cell dose, it appears that cell dose does influence the quality of T-cell reconstitution. The dog that received the lowest dose of cells, 1 × 10 6 CD34 + cells/kg, exhibited a delayed T-cell reconstitution with the absolute number of T-cells never reaching normal values and an inability to produce IgG-specific antibody. In contrast, all dogs that received >10 × 10 6 CD34 + cells/kg exhibited normal T-cell reconstitution based on the parameters examined. Although it is clear that the dose of CD34 + cells appears to influence T-cell reconstitution, the effect of cell dose on reconstitution of normal humoral immune function is less clear. In general, the dogs that received the higher doses of CD34 + bone marrow cells appeared to be better able to produce IgG-specific antibody following immunization. Previous studies have also reported an association between CD34 + cell dose and rate of engraftment, with dogs receiving less than 10 6 CD34 + cells/kg exhibiting delayed neutrophil recovery and a markedly delayed platelet recovery [39] .
The development of donor-derived T-cells but variable engraftment of donor B-cells in the present study is similar to the outcomes observed in published reports of HLAidentical and T-cell-depleted haploidentical BMTs in human X-SCID patients. All human patients with successful transplantation show engraftment of donor T-cells and attain normal T-cell function, but few patients have engraftment of donor B-cells, with the majority having continual humoral immune deficiencies that require many of these patients to be maintained on intravenous immune globulin (IVIG) therapy [16, 17] . The presence of low levels of IgG antibody in canine and X-SCID patients who have not had engraftment of donor B-cells after BMT may be due to a γc-independent IL-4 signaling pathway [50, 51] . However, recent reports have suggested that normal effective humoral immunity in human X-SCID patients who undergo BMT can only be achieved by the engraftment of donor B-cells, even at low levels [17, 18] . Together, these findings indicate that the best way to attain functional humoral immunity following BMT is to ensure the engraftment of significant numbers of normal donor B-cells. The failure of many transplantation-treated X-SCID patients to show engraftment of significant numbers of donor B-cells suggests that much of the observed T-cell reconstitution is derived from either a small number of γc normal stem cells or committed lymphoid progenitors [52] . This derivation is possible because there is a selective advantage for a normal γc in lymphoid progenitors committed to the T-cell lineage. This developmental selective advantage does not apply to cells of the B-or myeloid lineage in humans or dogs. Therefore, the number of circulating γc High levels of such engraftment should be a major goal for any BMT or gene therapy approach to treatment of X-SCID, not only to ensure normal B-cell function and obviate the need for IVIG treatment, but also to ensure durable T-cell function, especially considering that the production of thymically derived T-cells appears to occur throughout adult life [53, 54] .
One method of achieving this result could be the use of pretransplantation conditioning. Nonmyeloablative conditioning of recipients using busulfan (8 mg/kg) and cyclophosphamide (200 mg/kg) has recently been reported not to influence donor B-cell engraftment following BMT of human X-SCID patients; however, true myeloablative therapy could potentially improve the likelihood of donor B-cell engraftment [17] . Although true cytoablative therapy prior to transplantation may improve the likelihood of donor B-cell engraftment, elucidation of the conditions allowing full immunologic reconstitution and engraftment of both donor B-and T-cells in X-SCID dogs receiving transplants without pretransplantation conditioning needs to be explored because cytoablation increases the risk of lifethreatening infections during the posttransplantation period and requires lengthy hospitalization, thus increasing the cost of BMT. In addition, long-term sequelae, including growth retardation, sterility, learning disabilities, and possible malignancies, have to be considered following the use of pretransplantation cytoablation [55, 56] . Pretransplantation conditioning may also have an adverse effect on the bone marrow, and possibly thymic, microenvironments, which would influence the outcome of the BMT [57] [58] [59] . In the absence of such a conditioning regimen, the engraftment of transplanted cells can essentially be viewed as a competitive repopulation in which the number of normal cells that are IgG-specific antibody responses to tetanus toxoid in X-SCID dogs after BMT. Serum samples were obtained prior to immunization and at weekly intervals following primary and secondary immunization (↑). An ELISA specific for tetanus toxoid was performed using 2-fold dilutions of serum starting at 1:250. Results of the dogs that underwent transplantation are compared with pooled sera from immunized healthy dogs.
infused is correlated with the amount of donor cell chimerism seen in the periphery [60] . Therefore, maximizing the number of normal cells that are infused, whether from healthy donors or transduced autologous cells, is of great importance. Donor B-cell engraftment was observed in our previous studies of transplantation of unfractionated bone marrow in X-SCID dogs [29, 30] as well as in some of the recipients in the present study in which CD34 + donor cells were used. In human X-SCID patients who receive transplants of either unfractionated marrow or T-cell-depleted marrow without myeloablative conditioning, donor B-cell engraftment is rarely observed [16, 17] . The higher frequency of donor B-cell engraftment in the X-SCID dogs may reflect either the larger number of CD34 + progenitor cells transplanted in the canine experiments or the increased B-cell progenitor content of the canine CD34 + cells from young puppies. We have observed that approximately 14% of the nucleated marrow cells from 2-to 3-week-old puppies are CD34 + cells (Suter et al., unpublished data). As a result, the recipients of unfractionated marrow received estimated doses of CD34 + cells as high as 20 × 10 6 cells/kg. Similar high cell doses were given to most of the recipients of purified CD34 + cells in the present study. These doses of CD34 + cells are significantly higher than those used in human histocompatible or haploidentical BMT and may contribute to the higher frequency of B-cell engraftment observed in the dogs. Additionally, the CD34 + cells from very young dogs may have a higher frequency of B-lymphoid progenitors. Data from transplantation of human CD34 + cells into immunodeficient mice or patients have suggested greater B-lymphoid potential from umbilical cord blood cells [61] [62] [63] [64] . It is possible that the CD34 + cells from the very young puppies used as donors in the present experiments are similar to umbilical cord blood cells in that they have a high potential for B-cell engraftment and generation. Thus, the canine experiments suggest several strategies to increase B-cell engraftment after nonmyeloablative transplantation, notably the use of high cell doses and very young donors.
Historically, the dog has been a valuable model for BMT, with many of the advances achieved in the dog being directly transferable to human clinical BMT protocols [65, 66] . In canine X-SCID, unlike mouse γc-deficiency, the role of the γc in lymphoid development and function is similar to humans, allowing canine X-SCID to serve as a unique large-animal preclinical model to determine the optimal conditions for both donor B-and T-cell engraftment following allogeneic CD34 + BMT. Determination of the optimal conditions for engraftment of CD34 + cells will also be directly applicable to gene therapy studies because CD34 + cells are currently the target for transduction protocols.
